Nonalcoholic Fatty Liver Disease: Making the Diagnosis
Tooba Tariq, Archita P. Desai – 4 September 2020
Association of Sarcopenia and NAFLD: An Overview
Andrew A. Li, Donghee Kim, Aijaz Ahmed – 4 September 2020
Variation in Bile Microbiome by the Etiology of Cholestatic Liver Disease
Olaf Tyc, Christian Jansen, Robert Schierwagen, Frank Erhard Uschner, Mads Israelsen, Sabine Klein, Cristina Ortiz, Christian P. Strassburg, Stefan Zeuzem, Wenyi Gu, Sandra Torres, Michael Praktiknjo, Stephan Kersting, Melanie Langheinrich, Jacob Nattermann, Florence Servant, Manimozhiyan Arumugam, Aleksander Krag, Benjamin Lelouvier, Tobias J. Weismüller, Jonel Trebicka – 3 September 2020
Loss of Hepatic Carcinoembryonic Antigen‐Related Cell Adhesion Molecule 1 Links Nonalcoholic Steatohepatitis to Atherosclerosis
Hilda E. Ghadieh, Raghd Abu Helal, Harrison T. Muturi, Daniella D. Issa, Lucia Russo, Simon L. Abdallah, John A. Najjar, Fabian Benencia, Guillermo Vazquez, Wei Li, Sonia M. Najjar – 3 September 2020 – Patients with nonalcoholic fatty liver disease/steatohepatitis (NAFLD/NASH) commonly develop atherosclerosis through a mechanism that is not well delineated. These diseases are associated with steatosis, inflammation, oxidative stress, and fibrosis. The role of insulin resistance in their pathogenesis remains controversial.
Fatty Liver Disease: Metabolic, Genetic, or Both?
Heinz Zoller, Sonja Wagner, Benedikt Schaefer – 3 September 2020
Issue Information
3 September 2020
LiverLearning®: 2020 Webinar: Global Public Health Strategies for the Prevention of ALD in 2020
Alcohol-associated liver disease (ALD) is the leading cause of cirrhosis worldwide. Harmful drinking, especially among youth and women, is increasing. A global alliance and discussion about effective public health strategies is needed.
Nonalcoholic Fatty Liver Disease Impairs the Liver–Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis
Julie Steen Pedersen, Marte Opseth Rygg, Viggo Bjerregaard Kristiansen, Beth Hærstedt Olsen, Reza Rafiolsadat Serizawa, Jens Juul Holst, Sten Madsbad, Lise Lotte Gluud, Flemming Bendtsen, Nicolai Jacob Wewer Albrechtsen – 1 September 2020 – Nonalcoholic fatty liver disease (NAFLD) is associated with impaired hepatic actions of glucagon and insulin. Glucagon and amino acids are linked in an endocrine feedback circuit, the liver–alpha cell axis, that may be disrupted by NAFLD.
Gain of LINC00624 Enhances Liver Cancer Progression by Disrupting the Histone Deacetylase 6/Tripartite Motif Containing 28/Zinc Finger Protein 354C Corepressor Complex
Zhe Li, Xinyuan Lu, Yanfang Liu, Jingjing Zhao, Shengzhe Ma, Haoxiang Yin, Shenglin Huang, Yingjun Zhao, Xianghuo He – 1 September 2020
Exploratory Study of Autoantibody Profiling in Drug‐Induced Liver Injury with an Autoimmune Phenotype
Craig Lammert, Chengsong Zhu, Yun Lian, Indu Raman, George Eckert, Quan‐Zhen Li, Naga Chalasani – 1 September 2020 – Drug‐induced liver injury (DILI) sometimes presents with an autoimmune hepatitis‐like phenotype (AI‐DILI), and it is challenging to distinguish it from de novo autoimmune hepatitis (AIH). We conducted a study to identify autoantibodies unique to AI‐DILI by profiling serum autoantibodies.